Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy. Issue 4 (15th June 2016)

• Record Type: Journal Article
• Authors: Salati, Massimiliano; Tarantino, Vittoria; Maiorana, Antonino; Bettelli, Stefania; Luminari, Stefano
• Is Part Of: Hematological oncology. Volume 35:Issue 4(2017:Dec.)
• Page Start: 861
• Page End: 863
• Publication Date: 2016-06-15
• Subjects: double‐hit lymphoma -- lenalidomide -- CNS lymphoma; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2315
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B‐cell lymphoma and presents as leptomeningeal dissemination in two‐thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6‐positive double‐hit diffuse large B‐cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single‐agent lenalidomide following salvage chemotherapy. Copyright © 2016 John Wiley & Sons, Ltd.